| Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study EEW Cohen, D Soulières, C Le Tourneau, J Dinis, L Licitra, MJ Ahn, ... The Lancet 393 (10167), 156-167, 2019 | 1438 | 2019 |
| Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy CH Ries, MA Cannarile, S Hoves, J Benz, K Wartha, V Runza, ... Cancer cell 25 (6), 846-859, 2014 | 1344 | 2014 |
| Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept … C Le Tourneau, JP Delord, A Gonçalves, C Gavoille, C Dubot, N Isambert, ... The lancet oncology 16 (13), 1324-1334, 2015 | 1099 | 2015 |
| Dose escalation methods in phase I cancer clinical trials C Le Tourneau, JJ Lee, LL Siu JNCI: Journal of the National Cancer Institute 101 (10), 708-720, 2009 | 979 | 2009 |
| Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma E Saâda-Bouzid, C Defaucheux, A Karabajakian, VP Coloma, V Servois, ... Annals of Oncology 28 (7), 1605-1611, 2017 | 606 | 2017 |
| Genomic characterization of metastatic breast cancers F Bertucci, CKY Ng, A Patsouris, N Droin, S Piscuoglio, N Carbuccia, ... Nature 569 (7757), 560-564, 2019 | 583 | 2019 |
| Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1–positive cervical cancer: results from the phase Ib KEYNOTE-028 trial JS Frenel, C Le Tourneau, B O’Neil, PA Ott, SA Piha-Paul, C Gomez-Roca, ... Journal of Clinical Oncology 35 (36), 4035-4041, 2017 | 468 | 2017 |
| Novel patterns of response under immunotherapy E Borcoman, Y Kanjanapan, S Champiat, S Kato, V Servois, R Kurzrock, ... Annals of Oncology 30 (3), 385-396, 2019 | 462 | 2019 |
| Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1–positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study C Hsu, SH Lee, S Ejadi, C Even, RB Cohen, C Le Tourneau, JM Mehnert, ... Journal of Clinical Oncology 35 (36), 4050-4056, 2017 | 431 | 2017 |
| Mutational profile of metastatic breast cancers: a retrospective analysis C Lefebvre, T Bachelot, T Filleron, M Pedrero, M Campone, JC Soria, ... PLoS medicine 13 (12), e1002201, 2016 | 381 | 2016 |
| CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study PA Cassier, A Italiano, CA Gomez-Roca, C Le Tourneau, M Toulmonde, ... The Lancet Oncology 16 (8), 949-956, 2015 | 360 | 2015 |
| Safety and antitumor activity of pembrolizumab in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer HS Rugo, JP Delord, SA Im, PA Ott, SA Piha-Paul, PL Bedard, J Sachdev, ... Clinical Cancer Research 24 (12), 2804-2811, 2018 | 326 | 2018 |
| Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types R Lebofsky, C Decraene, V Bernard, M Kamal, A Blin, Q Leroy, TR Frio, ... Molecular oncology 9 (4), 783-790, 2015 | 294 | 2015 |
| Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST) C Le Tourneau, E Raymond, S Faivre Therapeutics and clinical risk management 3 (2), 341-348, 2007 | 257 | 2007 |
| Patterns of response and progression to immunotherapy E Borcoman, A Nandikolla, G Long, S Goel, C Le Tourneau American Society of Clinical Oncology Educational Book 38, 169-178, 2018 | 255 | 2018 |
| Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer F Mosele, B Stefanovska, A Lusque, AT Dien, I Garberis, N Droin, ... Annals of Oncology 31 (3), 377-386, 2020 | 254 | 2020 |
| FDG PET/CT for assessing tumour response to immunotherapy: Report on the EANM symposium on immune modulation and recent review of the literature N Aide, RJ Hicks, C Le Tourneau, S Lheureux, S Fanti, E Lopci European journal of nuclear medicine and molecular imaging 46, 238-250, 2019 | 229 | 2019 |
| Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies C Le Tourneau, S Faivre, V Laurence, C Delbaldo, K Vera, V Girre, ... European journal of cancer 46 (18), 3243-3250, 2010 | 187 | 2010 |
| Pembrolizumab for the treatment of advanced salivary gland carcinoma: findings of the phase 1b KEYNOTE-028 study RB Cohen, JP Delord, T Doi, SA Piha-Paul, SV Liu, J Gilbert, AP Algazi, ... American journal of clinical oncology 41 (11), 1083-1088, 2018 | 180 | 2018 |
| Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial C Le Tourneau, C Hoimes, C Zarwan, DJ Wong, S Bauer, R Claus, ... Journal for immunotherapy of cancer 6, 1-9, 2018 | 156 | 2018 |
